News

American Council on Science and Health5d
Cutting-Edge Immunotherapy Offers New Hope for Glioblastoma Patients
Newly discovered oncology drugs called “DNA-encoded tri-specific T-cell engagers,” or “DTriTEs,” engage the immune system ...
American Association of Individual Investors5d
Why Nektar Therapeutics’s (NKTR) Stock Is Down 5.47%
Nektar Therapeutics’s NKTR share price has dipped by 5.47%, which has investors questioning if this is right time to buy.
MedPage Today3d
Novel IL-7 Receptor Antagonist Shows Promise in Ulcerative Colitis
tumor necrosis factor inhibitors, vedolizumab (Entyvio), or ustekinumab (Stelara). Of these patients, 35 received 450 mg of intravenous lusvertikimab, 50 received a 850-mg dose, and 49 received ...
Medscape3d
Lymphoma and CAR T–Related Renal Injury: Assessing the Risks
New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...
Nektar Therapeutics Reports First Quarter 2025 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash ...
The Manila Times3d
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.
INmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune ...